“ur finding enables the safe discontinuation of follow-up after 6 years, leading to an improvement in quality of life and a reduction in health care system costs,” study researchers wrote.
Pastorino and colleagues noted that defining cure in stage II and III colon cancer has been challenging for two reasons: It is difficult to determine the threshold at which the chances of relapse ...
The concept of a cure in oncology, particularly for stage II and III colon cancer (CC), has historically suffered from ...
Colon cancer recurrence risk falls below 0.5% at 6 years post-surgery, offering a practical benchmark for defining cure, according to new research.
Entitled “International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma,” the peer-reviewed article, published online on ...
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.